ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,685.56
      -0.49%
      US Tech 100
      19,158.80
      -0.91%
      Dow Jones
      41,915.70
      -0.26%
      Brent Oil
      73.855
      -0.63%
      Bitcoin
      63,010.46
      0.10%
      Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ

      6. Syndax Pharmaceuticals Inc (SNDX) Quote

      Syndax Pharmaceuticals Inc

      Syndax Pharmaceuticals Inc (SNDX)

      NASDAQ
      18.66
      0.03
      ( 0.16% )
      Updated: 11:18:55
      Delayed by 15 minutes

      Professional-Grade Tools, for Individual Investors.

      Premium

      Key stats and details

      Current Price
      18.66
      Bid
      18.65
      Ask
      18.68
      Volume
      243,406
      18.44 Day's Range 18.69
      11.215 52 Week Range 25.34
      Market Cap
      1.588B
      Previous Close
      18.63
      Open
      18.64
      Last Trade
      3
      @
      18.6651
      Last Trade Time
      11:19:11
      Financial Volume
      $ 4,535,213
      VWAP
      18.6323
      Average Volume (3m)
      1,053,729
      Shares Outstanding
      85,096,358
      Dividend Yield
      -
      PE Ratio
      -7.58
      Earnings Per Share (EPS)
      -2.46
      Revenue
      -
      Net Profit
      -209.36M

      About Syndax Pharmaceuticals Inc

      Syndax Pharmaceuticals Inc is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company's product candidates are entinostat which has direct effects on both cancer cells and immune regulatory cells, SNDX-6352 and ... Syndax Pharmaceuticals Inc is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company's product candidates are entinostat which has direct effects on both cancer cells and immune regulatory cells, SNDX-6352 and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Business activity of the group is primarily functioned through the region of United States. Show more

      Sector
      Pharmaceutical Preparations
      Industry
      Pharmaceutical Preparations
      Website
      www.syndax.com
      Headquarters
      Wilmington, Delaware, USA
      Founded
      -
      Syndax Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker SNDX. The last closing price for Syndax Pharmaceuticals was $18.63. Over the last year, Syndax Pharmaceuticals shares have traded in a share price range of $ 11.215 to $ 25.34.

      Syndax Pharmaceuticals currently has 85,096,358 shares outstanding. The market capitalization of Syndax Pharmaceuticals is $1.59 billion. Syndax Pharmaceuticals has a price to earnings ratio (PE ratio) of -7.58.

      Ask ADVFN Intelligence (AI)

      Syndax Pharmaceuticals (SNDX) Options Flow Summary

      SNDX Options Flow

      Overall Flow

      Bullish

      Net Premium

      234k

      Calls / Puts

      500.00%

      Buys / Sells

      100.00%

      OTM / ITM

      100.00%

      Sweeps Ratio

      0.00%

      SNDX Latest News

      More News

      Incyte and Syndax Announce New England Journal of Medicine Publication of Data from Pivotal AGAVE-201 Trial of Niktimvo™ (axatilimab-csfr) in Chronic Graft-Versus-Host Disease

      Incyte and Syndax Announce New England Journal of Medicine Publication of Data from Pivotal AGAVE-201 Trial of Niktimvo™ (axatilimab-csfr) in Chronic Graft-Versus-Host Disease PR...

      September 18 2024
      PR Newswire (US)

      Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

      Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire WALTHAM, Mass., Sept. 6, 2024 WALTHAM, Mass., Sept. 6, 2024 /PRNewswire/ -- Syndax...

      September 06 2024
      PR Newswire (US)

      Incyte und Syndax melden FDA-Zulassung von Niktimvo™ (Axatilimab-csfr) zur Behandlung der chronischen Graft-versus-Host-Krankheit (GvHD)

      Niktimvo™ (Axatilimab-csfr) ist der erste zugelassene Anti-CSF-1R-Antikörper, der auf die Ursachen von Entzündung und Fibrose bei chronischer GvHD abzielt Daten der AGAVE-201-Studie, die die...

      August 15 2024
      Business Wire

      Incyte et Syndax annoncent l’approbation par la FDA américaine de Niktimvo™ (axatilimab-csfr) pour le traitement de la maladie chronique du greffon contre l’hôte (GVHD)

      Niktimvo™ (axatilimab-csfr) est le premier anticorps anti-CSF-1R autorisé à cibler les moteurs de l’inflammation et de la fibrose observés dans la GVHD chronique Les données clés de l’étude...

      August 15 2024
      Business Wire

      Incyte and Syndax Announce U.S. FDA Approval of Niktimvo™ (axatilimab-csfr) for the Treatment of Chronic Graft-Versus-Host Disease (GVHD)

      Niktimvo™ (axatilimab-csfr) is the first approved anti-CSF-1R antibody targeting the drivers of inflammation and fibrosis seen in chronic GVHD Pivotal data from the AGAVE-201 study supporting...

      August 14 2024
      Business Wire

      Syndax Announces Publication in the Journal of Clinical Oncology of Data from the Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia

      Syndax Announces Publication in the Journal of Clinical Oncology of Data from the Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia PR Newswire WALTHAM, Mass...

      August 12 2024
      PR Newswire (US)

      Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

      Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire WALTHAM, Mass., Aug. 5, 2024 WALTHAM, Mass., Aug. 5, 2024 /PRNewswire/ -- Syndax...

      August 05 2024
      PR Newswire (US)

      Syndax Reports Second Quarter 2024 Financial Results and Provides Clinical and Business Update

      Syndax Reports Second Quarter 2024 Financial Results and Provides Clinical and Business Update PR Newswire WALTHAM, Mass., Aug. 1, 2024 –  Axatilimab BLA in refractory chronic GVHD is under...

      August 01 2024
      PR Newswire (US)

      Form 10-Q - Quarterly report [Sections 13 or 15(d)]

      August 01 2024
      Edgar (US Regulatory)

      Form 8-K - Current report

      August 01 2024
      Edgar (US Regulatory)
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      10.3051.6616725687818.35519.3317.34141745218.34841757CS
      4-1.87-9.1086215294720.5321.5617.34109419819.00822313CS
      12-2.07-9.9855282199720.7325.0717.34105372920.78988586CS
      26-3.66-16.397849462422.3225.0717.34103550320.92536821CS
      521.629.5070422535217.0425.3411.215136582518.76756134CS
      156-0.52-2.7111574556819.1829.8611.21593113519.73207208CS
      2609.95114.2365097598.7129.865.3576637519.18643614CS

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      XPONExpion360 Inc
      $ 0.175
      (200.69%)
      		982.01M
      BNZIBanzai International Inc
      $ 6.4999
      (125.69%)
      		46.8M
      LFLYLeafly Holdings Inc
      $ 2.62
      (46.37%)
      		24.54M
      INVZWInnoviz Technologies Ltd
      $ 0.149
      (35.08%)
      		262
      VERBVerb Technology Company Inc
      $ 0.0739
      (32.91%)
      		121.93M
      GSIWGarden Stage Ltd
      $ 2.93
      (-62.58%)
      		5.94M
      CRBPCorbus Pharmaceuticals Holdings Inc
      $ 21.12
      (-59.15%)
      		7.18M
      LGCBLinkage Global Inc
      $ 0.41256
      (-58.28%)
      		1.37M
      SKYESkye Bioscience Inc
      $ 2.9889
      (-45.56%)
      		1.83M
      KOPNKopin Corporation
      $ 0.6502
      (-32.56%)
      		6.55M
      XPONExpion360 Inc
      $ 0.1779
      (205.67%)
      		981.59M
      VERBVerb Technology Company Inc
      $ 0.074
      (33.09%)
      		121.93M
      NVDANVIDIA Corporation
      $ 115.7993
      (-1.76%)
      		107.82M
      SQQQProShares UltraPro Short QQQ
      $ 7.985
      (2.90%)
      		64.14M
      HOLOMicroCloud Hologram Inc
      $ 0.244
      (5.35%)
      		60.84M

      SNDX Discussion

      View Posts
      dinogreeves dinogreeves 5 days ago
      Have you looked at TIL on Friday.
      👍️0
      Monksdream Monksdream 5 days ago
      SNDX a buy again
      👍️0
      dinogreeves dinogreeves 12 months ago
      SNDX had the highest volume today for some reason, this is either going to tank hard on Monday or hit 30...50....60 dollars. Took my chances with 600 shares.
      👍️0
      dinogreeves dinogreeves 12 months ago
      Possibly a huge run on Monday, very possible or they missed the trial. Huge 400 million in the coffers and monster institutional ownership.
      👍️0
      dealerschool2006 dealerschool2006 3 years ago
      Nice rebound today for $SNDX, beat the street and conference call was successful!!!
      👍️0
      dealerschool2006 dealerschool2006 3 years ago
      SNDX recovering from panic sale!!!
      👍️0
      dealerschool2006 dealerschool2006 3 years ago
      Panic sale for SNDX on positive results...May options wide swings...
      👍️0
      DaytraderJohn DaytraderJohn 4 years ago
      Its interesting how a company such as this can go on to have revenue loss of 50m+ per year. Yet still give higher ups 200k+ cash bonuses and large salaries.

      They have no product revenue.

      I expect shares to be diluted after earnings.

      Read their 10k. I guess it's a gamble play incase one day they do get approval.
      👍️0
      BoilerRoom BoilerRoom 5 years ago
      $SNDX looks like this run is going to continue. Let’s hit $15.00 this week folks
      👍️0
      ClayTrader ClayTrader 5 years ago
      * * $SNDX Video Chart 01-31-2020 * *

      Link to Video - click here to watch the technical chart video

      👍️0
      BoilerRoom BoilerRoom 5 years ago
      $SNDX next week is going to be fun
      👍️0
      BoilerRoom BoilerRoom 5 years ago
      $SNDX Hope you guys went all in here...Have a great weekend see y’all on Monday
      👍️0
      BoilerRoom BoilerRoom 5 years ago
      $SNDX holding this baby!
      👍️0
      BoilerRoom BoilerRoom 5 years ago
      $SNDX keep climbing baby! Going be going up all next week
      👍️0
      BoilerRoom BoilerRoom 5 years ago
      $SNDX looking awesome from my call at $8.00
      👍️0
      BoilerRoom BoilerRoom 5 years ago
      $SNDX got us a runner folks!!!
      👍️0
      BoilerRoom BoilerRoom 5 years ago
      $SNDX Chomp Chomp Chomp!
      👍️0
      BoilerRoom BoilerRoom 5 years ago
      $SNDX Weeeeeeeeeee
      👍️0
      BoilerRoom BoilerRoom 5 years ago
      Going to run folks.
      👍️0
      BoilerRoom BoilerRoom 5 years ago
      $SNDX in at $8.00
      👍️0
      TheFinalCD TheFinalCD 5 years ago
      News News Alert: Syndax Announces $35.0 Million Offering of Common Stock...
      👍️0
      whytestocks whytestocks 5 years ago
      News: $SNDX Syndax Announces $26.2 Million Offering of Common Stock and Warrants

      WALTHAM, Mass. , March 27, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax" or the "Company") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it has entered into an agreement with Biotechnolo...

      Find out more https://marketwirenews.com/news-releases/syndax-announces-26-2-million-offering-of-common-stock-and-warrants-7897910.html
      👍️0
      DewDiligence DewDiligence 6 years ago
      SNDX 3Q18 results—cash=$89.6M:

      https://www.prnewswire.com/news-releases/syndax-pharmaceuticals-reports-third-quarter-2018-financial-results-and-provides-clinical-and-business-update-300744153.html
      👍️0
      Spartak Spartak 6 years ago
      Well, the company is done. What a disaster.
      👍️0
      DewDiligence DewDiligence 6 years ago
      SNDX -21%/AH on PFS failure in HR+/HER2- breast cancer:

      https://finance.yahoo.com/news/syndax-host-conference-call-phase-200500374.html

      The trial continues to test for statsig OS every six months until Nov 2019.
      👍️0
      DewDiligence DewDiligence 6 years ago
      SNDX -20% on no news—sell-off could be related to recent general bearishness for PD-(L1) add-on agents, which was a theme at ESMO.
      👍️0
      DewDiligence DewDiligence 6 years ago
      SNDX upgrades BoD:

      https://www.prnewswire.com/news-releases/syndax-announces-changes-to-its-board-of-directors-300718661.html
      👍️0
      DewDiligence DewDiligence 6 years ago
      #msg-143766395
      👍️0
      DewDiligence DewDiligence 6 years ago
      SNDX phase-3 PFS data now expected in 4Q18 (rather than 3Q18); I essentially called this back in May (#msg-140923103, bottom):

      https://www.prnewswire.com/news-releases/syndax-announces-updated-results-from-phase-2-encore-601-trial-of-entinostat-in-combination-with-keytruda-pembrolizumab-in-non-small-cell-lung-cancer-300717717.html
      👍️0
      DewDiligence DewDiligence 6 years ago
      #msg-143642544
      👍️0
      DewDiligence DewDiligence 6 years ago
      SNDX 2Q18 CC transcript:

      https://finance.yahoo.com/news/edited-transcript-sndx-earnings-conference-152734163.html
      👍️0
      DewDiligence DewDiligence 6 years ago
      SNDX 2Q18 items—6/30/18 cash=$98.4M…

      PR:
      http://ir.syndax.com/news-releases/news-release-details/syndax-pharmaceuticals-reports-second-quarter-2018-financial

      CC slides:
      http://ir.syndax.com/static-files/18eaf63a-6c93-45cd-8272-60479300c153
      👍️0
      Spartak Spartak 6 years ago
      When does pounding stop? Someone hummers it pretty badly.
      👍️0
      fsantes fsantes 6 years ago
      Ill keep a look out for some then!... I’ve been looking as well. Thank you!
      👍️0
      DewDiligence DewDiligence 6 years ago
      No. I generally post anything that's material.
      👍️0
      fsantes fsantes 6 years ago
      Have you heard any new news on SNDX?
      👍️0
      fsantes fsantes 6 years ago
      I really appreciate it. Bought some shares as one advisor mentioned it to me but keeping track of what’s going on on it
      👍️0
      DewDiligence DewDiligence 6 years ago
      SNDX requested that the SEC keep this document in redacted form:

      https://www.sec.gov/Archives/edgar/data/1395937/000156459018012378/sndx-ex101_169.htm

      This was filed as an exhibit to the most recent 10-Q.
      👍️0
      fsantes fsantes 6 years ago
      Do you know what’s the news that came out about? When I look it’s blank..
      👍️0
      DewDiligence DewDiligence 6 years ago
      SNDX, NKTR ink clinical-trial collaboration for Entinostat + NK-214 in second-lime melanoma:

      https://www.prnewswire.com/news-releases/syndax-and-nektar-therapeutics-announce-immuno-oncology-clinical-trial-collaboration-300656793.html

      NKTR is furnishing free drug for the phase-1/2 clinical trial, but no cash.
      👍️0
      DewDiligence DewDiligence 6 years ago
      SNDX ENCORE-601 update…

      PR:
      https://www.prnewswire.com/news-releases/syndax-announces-updated-results-from-phase-2-encore-601-trial-of-entinostat-in-combination-with-keytruda-pembrolizumab-300650233.html

      CC slides:
      http://ir.syndax.com/static-files/7c0c8627-0b81-43d6-9210-6cb02684db5f
      👍️0
      tika1 tika1 6 years ago
      After failure of two high profile IO combination, I think SNDX will go nowhere for its own IO combo.

      All eyes on Etinostat + exemestane only. Still chance of double, if that turns out good.
      👍️0
      DewDiligence DewDiligence 6 years ago
      Transcript of SNDX 1Q18 CC:

      https://finance.yahoo.com/news/edited-transcript-sndx-earnings-conference-235620976.html
      👍️0
      DewDiligence DewDiligence 6 years ago
      SNDX new investor slide set:

      http://ir.syndax.com/static-files/da19e99b-2bd2-4456-91fe-0e67b97fc0d0
      👍️0
      DewDiligence DewDiligence 6 years ago
      The 1Q18 10-Q has been filed:

      https://www.sec.gov/Archives/edgar/data/1395937/000156459018012378/sndx-10q_20180331.htm
      👍️0
      DewDiligence DewDiligence 6 years ago
      SNDX 1Q18 results—cash=$113M:

      https://www.prnewswire.com/news-releases/syndax-pharmaceuticals-reports-first-quarter-2018-financial-results-and-provides-clinical-and-business-update-300644832.html
      👍️0
      DewDiligence DewDiligence 6 years ago
      SNDX ASCO lineup:

      https://finance.yahoo.com/news/syndax-pharmaceuticals-announces-presentations-2018-200500073.html
      👍️0
      DewDiligence DewDiligence 6 years ago
      Yes—please see my reply in #msg-140012720.
      👍️0
      tika1 tika1 6 years ago
      Dew,
      Is there any hope for success of this trial after high profile INCY failure? What is your take on SNDX current weakness?


      Oral Presentations:

      Title: Safety, efficacy, and immune correlates of alternative doses and schedules of entinostat combined with pembrolizumab in patients with advanced solid tumors - results from SNDX-275-0141 phase I trial
      Presenter: Anthony W. Tolcher, M.D.
      Category: Clinical Trials
      Session: Biomarkers in Immuno-oncology
      Abstract Number: CT179
      Location: N Hall C - McCormick Place North (Level 1)
      Date and Time: Tuesday April 17, 2018; 3:50 PM - 4:05 PM C.T.
      👍️0
      DewDiligence DewDiligence 6 years ago
      SNDX presentation lineup at AACR:

      https://finance.yahoo.com/news/syndax-present-2018-american-association-110000742.html
      👍️0

      Your Recent History

      NASDAQ
      SNDX
      Syndax Pharmaceuticals
      Delayed Upgrade Clock